
The use of GLP-1 medications continues to surge, driven by their promise in the outcomes they produce. There is significant clinical evidence that these drugs can lead to weight loss, help people sustain that weight loss, and likely reduce the prevalence of strokes, heart attacks, and other diseases. However, this rapid shift in consumer demand for these drugs presents employers with an immediate challenge: how to manage the clinical and financial impact of these high-cost, in-demand drugs. A recent report from Aon found that when GLP-1s are successful, companies save approximately $1,500 in medical claims, but employers still report that the cost of the drug is about $7,000 per year net of rebates.
This dynamic is rapidly reshaping pharmacy spending and benefits planning, and it’s just the beginning. According to a recent FAIR Health report, approximately 4% of Americans took GLP-1 drugs in 2024 to address overweight issues, obesity, or Type 2 diabetes. However, the clinical need is far greater than this: in 2024, more than 80% of patients with an overweight or obesity diagnosis did not receive a GLP-1 prescription, bariatric surgery, or behavioral health service. As awareness and demand for these drugs increase, employers are faced with designing strategies that support the health and wellbeing of their employees while mitigating costs.
Here are five guidelines to help employers balance health outcomes and financial responsibility to ensure that GLP-1 coverage is effective, affordable, and aligned with improved health and workforce well-being for employees and their families.
1. Optimize PBM performance
Employers need to proactively engage with Pharmacy Benefit Managers (PBMs). The first step is to shift the way PBMs are compensated, moving from models that reward higher drug spending to flat per member per month (PMPM) fees, and insist that PBMs act as full partners in executing your strategy – you are their customer.
Employers should have full visibility into drug pricing, manufacturer rebates, and the methods used for utilization management, particularly regarding GLP-1s and other specialty drugs. Prior authorization protocols must be implemented to control inappropriate utilization, including clear criteria tied to dosage limits, patient demographics, and step therapy requirements. Additionally, employers should request data on prior authorization approval rates, targeting a threshold below 75% to ensure that only clinically appropriate prescriptions are approved.
Finally, during PBM procurement and contract discussions, employers should ask pointed questions like, “What about my drug mix?”, with the goal of controlling costs, sharing financial risk, and aligning with the plan sponsor’s long-term financial objectives.
2. Control spending with clinical and weight management programs
A successful GLP-1 strategy goes beyond medication access. Employers and health plans should use aggregated data to proactively identify high-risk members and deploy targeted interventions, such as personalized weight management or lifestyle coaching programs. This allows plans to address root causes before they escalate into more expensive or acute care needs.
GLP-1s must be integrated into a broader, value-based care strategy rather than treating them as a single, one-off solution. Encouraging patients to participate in targeted lifestyle or weight-loss programs supports the appropriate usage of medications while also creating long-term behavior change.
The key to success is to cultivate a sense of shared responsibility among employees. Promoting healthier behaviors – like appropriate nutrition, regular physical activity, and adherence to prescribed medications – ensures that employees are active participants in their health outcomes.
3. Improve price transparency
Empowering employees to make informed, cost-conscious healthcare decisions begins with transparency. When patients understand the costs of care before filling a prescription, they are better equipped to navigate their healthcare costs. Transparent plan design should also steer members toward high-value care options, which includes identifying providers and services that deliver quality care at a fair cost.
4. Require value-based purchasing from drug manufacturers
Drug pricing must be directly tied to the health outcomes the medication delivers. Employers should require value-based agreements for these drugs as pharmaceutical companies can charge whatever they want for the drug. For example, if purchasing the drug results in fewer heart attacks and leads to cost savings, employers should share those savings with the drugmaker but also hold them accountable if the drug fails and doesn’t produce that benefit.
In tandem, a more sustainable model would be to compensate PBMs based on actual performance, measured by their ability to both improve health outcomes and manage pharmacy spending. Tying PBM earnings to results realigns incentives and ensures that PBMs are working towards a shared goal: delivering better health outcomes to patients at a price that reflects the true value of those outcomes.
5. Collaborate with other employers to disperse and diversify costs
Working together, employers can mitigate the short-term cost increases of GLP-1 usage while identifying and capitalizing on broader opportunities for value-based care, cost savings and better outcomes across a large, diverse patient population. Bringing large employers together with the collective goal of improving people’s lives and making healthcare more affordable can result in significant cost savings and better outcomes for employees and their families. Aligning benefit plans with provider incentives has a powerful impact on improving access, making high-quality care more affordable, and moving us closer to fixing our broken healthcare system.
Employers who implement these strategies, continue iterating over the long term, and invest in robust healthcare solutions will see reduced absenteeism, higher productivity, and improved employee retention. These benefits contribute to overall cost-effectiveness while ultimately – and most importantly – promoting better health outcomes and healthier lives for employees and their families.
Photo: Jason Dean, Getty Images
Robert E. Andrews is the Chief Executive Officer of the Health Transformation Alliance (HTA), an original author of the Affordable Care Act, and a former member of Congress. As CEO of the HTA, Andrews oversees the strategic direction of 70+ major corporations that have come together in an alliance to do one thing: fix our broken healthcare system. Formed by four founding members in September 2015, the HTA member companies collectively are responsible for more than 4 million employees in the United States with an annual healthcare spend of $27+ billion. Through Andrews' leadership, the HTA has launched value-driven solutions specifically designed to improve patient care and economic value through world-class data and analytics, pathbreaking pharmaceutical solutions, high-quality medical networks, and robust consumer engagement initiatives. To date, the cooperative has saved its member companies well over $2 billion in healthcare costs.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.